Homburg R, Eshel A, Abdalla H I, Jacobs H S
Cobbold Laboratories, Middlesex Hospital, London, UK.
Clin Endocrinol (Oxf). 1988 Jul;29(1):113-7. doi: 10.1111/j.1365-2265.1988.tb00252.x.
The addition of biosynthetic human growth hormone (GH) to treatment with human menopausal gonadotrophin (hMG) significantly augmented the ovarian response in four patients treated for in-vivo and three patients treated for in-vitro fertilization who had previously been resistant to hMG. The amount, duration of treatment and daily effective dose of hMG were all reduced by growth hormone. This action of growth hormone offers a new approach to ovulation induction.
在接受人绝经期促性腺激素(hMG)治疗的患者中添加生物合成人生长激素(GH),可显著增强卵巢反应。在4例接受体内受精治疗和3例接受体外受精治疗且此前对hMG耐药的患者中,均出现了这种情况。生长激素降低了hMG的用量、治疗持续时间和每日有效剂量。生长激素的这一作用为诱导排卵提供了一种新方法。